Lucid Diagnostics Inc LUCD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LUCD is a good fit for your portfolio.
News
-
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
-
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
-
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
-
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
-
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
-
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
-
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- $0.93
- Day Range
- $0.92–1.00
- 52-Week Range
- $0.63–1.85
- Bid/Ask
- $0.80 / $1.39
- Market Cap
- $47.02 Mil
- Volume/Avg
- 247,573 / 223,140
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.34
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 70
- Website
- https://www.luciddx.com
Comparables
Valuation
|
Metric
|
LUCD
|
HLVX
|
PODD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 64.55 |
Price/Book Value | — | 2.87 | 16.75 |
Price/Sales | 16.34 | — | 7.62 |
Price/Cash Flow | — | — | 38.44 |
Price/Earnings
LUCD
HLVX
PODD
Financial Strength
|
Metric
|
LUCD
|
HLVX
|
PODD
|
|---|---|---|---|
Quick Ratio | 0.64 | 10.37 | 2.36 |
Current Ratio | 0.75 | 10.62 | 3.51 |
Interest Coverage | −126.62 | −54.72 | 6.14 |
Quick Ratio
LUCD
HLVX
PODD
Profitability
|
Metric
|
LUCD
|
HLVX
|
PODD
|
|---|---|---|---|
Return on Assets (Normalized) | −116.01% | −34.03% | 7.81% |
Return on Equity (Normalized) | −5,682.94% | −42.52% | 30.26% |
Return on Invested Capital (Normalized) | −173.01% | −38.62% | 9.66% |
Return on Assets
LUCD
HLVX
PODD
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Lzhddmhy | Qrjrdc | $182.6 Bil | |
SYK
| Stryker Corp | Vwjbgzcwx | Hjsl | $125.9 Bil | |
MDT
| Medtronic PLC | Cnfgsvzn | Gthyct | $108.3 Bil | |
BSX
| Boston Scientific Corp | Hyzqwhzg | Pzspkd | $106.9 Bil | |
EW
| Edwards Lifesciences Corp | Ldmmcwsl | Rzjngwx | $52.3 Bil | |
DXCM
| DexCom Inc | Ljbjqhlng | Wtm | $50.3 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Vcpvqbchy | Wwss | $25.0 Bil | |
PHG
| Koninklijke Philips NV ADR | Mbvkbslq | Sckkygy | $24.3 Bil | |
ALGN
| Align Technology Inc | Wgdpmcb | Gvbfkp | $21.1 Bil | |
PODD
| Insulet Corp | Qtlcnntylr | Bzjcps | $12.4 Bil |